Navigation Links
Novel Technique Would Prevent Re-Clogged Arteries

Researchers at the Technion-Israel Institute of Technology are proposing a revolutionary approach to prevent the common post-balloon angioplasty problem// of restenosis (re-clogging of coronary arteries).

More than 1.2 million angioplasties were performed in the United States in 2003, according to the American Heart Association.

Angioplasty is a minimally invasive procedure, during which a tiny deflated balloon is inserted into clogged arteries and inflated to open blockages. In many cases, a stent – originally mounted on the balloon – is then positioned inside the artery, against the arterial wall. Blockages – caused not by new fatty deposits, but by tissue growth from the walls of the blood vessel – re-occur in more than one-third of patients. Such growths, which doctors relate to as they would a cancerous growth, are most often treated with “anti-proliferative” medications that prevent uncontrolled tissue growth.

Because of the site-specific nature of these growths, the drugs to treat them must be delivered only to the affected tissue. Stent manufacturers currently include such drugs in their products for slow release over a six-month period (during which time the risk for restenosis is highest). Precise control of this release process can be tricky, however, and restenosis still occurs in many patients.

The new, patented technique – developed in the Technion Department of Biomedical Engineering by Professor Noah Lotan, Dr. Sarit Sivan and Professor Uri Dinnar – begins when the patient swallows a "pro-drug" compound. Inactive by itself, this compound can be taken for as long as necessary without side effects. It is activated only when it comes into contact with a specific enzyme attached to the stent by its manufacturer. In effect, the enzyme on the stent then becomes a "pharmaceutical factory" that manufactures an active anti-proliferative drug.

According to lead researcher Lotan, the pro-drug is an amin o acid that is a safe and natural component of all proteins. When the risk of restenosis abates, patients could simply stop taking the pro-drug, and the stent would stop manufacturing the drug.

“This approach makes up a very general technological platform that can be applied for different medical problems,” said Lotan. “It has potential applications for every drug, known today or invented in the future, and could be useful for medications – including chemotherapy drugs – best administered to one very specific location in the body."

Source-Newwise
SRM
'"/>




Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients
8. Novel Therapy for Chronic Problem
9. Blood Sugar Kept In Control By Novel Protein
10. Novel antibiotic dressing developed for improved wound healing
11. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... 23, 2016 , , , ... 7, 2016 , , , , LOCATION: , , , ... , , , EXPERT PANELISTS:  , , , Frost & Sullivan,s ... Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program ... global pharmaceutical industry is witnessing an exceptional era. Several new demand ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
Breaking Medicine Technology: